A practical reference on 白蛋白结合: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-19 and is reviewed periodically as new material appears.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
=== Excretion === Bile is the major pathway for the excretion of copper and is vitally important in the control of liver copper levels. Most fecal copper results from biliary excretion; the remainder is derived from unabsorbed copper and copper from desquamated mucosal cells.
=== Custom Tags === ColdFusion provides several ways to implement custom markup language tags, i.e. those not included in the core ColdFusion language. These are especially useful for providing a familiar interface for web designers and content authors familiar with HTML but not imperative programming. The traditional and most common way is using CFML. A standard CFML page can be interpreted as a tag, with the tag name corresponding to the file name prefixed with "cf_". For example, the file IMAP.cfm can be used as the tag "cf_imap". Attributes used within the tag are available in the ATTRIBUTES scope of the tag implementation page. CFML pages are accessible in the same directory as the calling page, via a special directory in the ColdFusion web application, or via a CFIMPORT tag in the calling page. The latter method does not necessarily require the "cf_" prefix for the tag name. A second way is the developments of CFX tags using Java or C++. CFX tags are prefixed with "cfx_", for example "cfx_imap". Tags are added to the ColdFusion runtime environment using the ColdFusion administrator, where JAR or DLL files are registered as custom tags. Finally, ColdFusion supports JSP tag libraries from the JSP 2.0 language specification. JSP tags are included in CFML pages using the CFIMPORT tag.
It has been proposed that ubiquitin is the slowest-evolving protein identified to date. Ubiquitin contains seven lysine residues to which another ubiquitin can be ligated, resulting in different types of polyubiquitin chains. Chains in which each additional ubiquitin is linked to lysine 48 of the previous ubiquitin have a role in proteasome targeting, while other types of chains may be involved in other processes.
== Research == Insulin was discovered in 1921, by Frederick Banting, Charles Best and John Macleod at the University of Toronto. At a time when most child diabetics lived no more than months or a few years, insulin offered the hope of extending lives. Somogyi worked with Philip A. Shaffer and Edward Adelbert Doisy on insulin preparation and insulin's use in the treatment of diabetes. He developed a method for extracting insulin from the pancreases of dogs. In 1922 doctors treated the first diabetic American child, a baby boy, with Somogyi's insulin. Somogyi also developed a quicker, less expensive method for screening for diabetes, using sodium carbonate, urine, and heat. This led to the development of popular tests, including several varieties of urine sugar comparator from the Aloe Company of Saint Louis, Missouri. Urine Sugar Test kits were also produced by Eli Lilly and Company.
Sources: en.wikipedia.org
Subclass Nautiloidea: Fundamental ectocochliate cephalopods that provided the source for the Ammonoidea and Coleoidea. Order † Plectronocerida: the ancestral cephalopods from the Cambrian Period Order † Ellesmerocerida (500 to 470 Ma) Order † Endocerida (485 to 430 Ma) Order † Actinocerida (480 to 312 Ma) Order † Discosorida (482 to 392 Ma) Order † Pseudorthocerida (432 to 272 Ma) Order † Tarphycerida (485 to 386 Ma) Order † Oncocerida (478.5 to 324 Ma) Order Nautilida (extant; 410.5 Ma to present) Order † Orthocerida (482.5 to 211.5 Ma) Order † Ascocerida (478 to 412 Ma) Order † Bactritida (418.1 to 260.5 Ma) Subclass † Ammonoidea: ammonites (479 to 66 Ma) Order † Goniatitida (388.5 to 252 Ma) Order † Ceratitida (254 to 200 Ma) Order † Ammonitida (215 to 66 Ma) Subclass Coleoidea (410.0 Ma-Rec) Cohort † Belemnoidea: Belemnites and kin Genus † Jeletzkya Order † Aulacocerida (265 to 183 Ma) Order † Phragmoteuthida (189.6 to 183 Ma) Order † Hematitida (339.4 to 318.1 Ma) Order † Belemnitida (339.4 to 66 Ma) Genus † Belemnoteuthis (189.6 to 183 Ma) Cohort Neocoleoidea Superorder Decapodiformes (also known as Decabrachia or Decembranchiata) Order Spirulida: ram's horn squid Order Sepiida: cuttlefish Order Sepiolida: pygmy, bobtail and bottletail squid Order Idiosepida Order Oegopsida: neritic squid Order Myopsida: coastal squid Order Bathyteuthida Superorder Octopodiformes (also known as Vampyropoda) Family † Trachyteuthididae Order Vampyromorphida: vampire squid Order Octopoda: octopus Superorder † Palaeoteuthomorpha Order † Boletzkyida Other classifications differ, primarily in how the various decapod orders are related, and whether they should be orders or families.
There is great potential for RNA interference (RNAi) to be used therapeutically to reversibly silence any gene. For RNAi to realize its therapeutic potential, small interfering RNA (siRNA) must be delivered to the site of action in the cells of target tissues. But finding safe and efficient delivery mechanisms is a major obstacle to achieving the full potential of siRNA-based therapies. Unmodified siRNA is unstable in the bloodstream, has the potential to cause immunogenicity, and has difficulty readily navigating cell membranes. As a result, chemical alterations and/or delivery tools are needed to safely transfer siRNA to its site of action. The majority of approved agents use N-acetylgalactosamine (GalNAc) conjugation to achieve selective hepatocyte delivery via the asialoglycoprotein receptor (ASGPR), enabling subcutaneous administration. Patisiran (Onpattro), the first approved siRNA drug (2018), instead employs a lipid nanoparticle (LNP) formulation for intravenous delivery.
== Mechanisms == The mechanisms by which healthy cells transform into cancer cells are described in detail elsewhere (see Cancer main page; Carcinogenesis main page). The precise molecular changes that result in sarcoma are not always known, but certain types of sarcomas are associated with particular genetic mutations. Examples include:
Sources: en.wikipedia.org
===== Replacement ===== Some ingredients originating from endangered or otherwise rare species have widely (but not universally) recognized alternatives. For example, rhinoceros horn is generally replaced with a buffalo horn "concentrate powder", a practice adopted by the Chinese Pharmacopoeia. Tiger bone has been replaced with a mixture of bone powders from three livestock species in a Chinese patent medicine approved as a prescription drug in China. More
In the English-speaking world, interpretations of Byzantine history frequently surface in political debates, alongside the growing appreciation for its legacy. The complexity of this history makes it a sensitive topic, especially regarding Greece's role in Europe's evolving sense of identity and the origin stories of many European nations.
Similar behavior is exhibited by some iron compounds, such as the ferrites including the mineral magnetite, a crystalline form of the mixed iron(II,III) oxide Fe3O4 (although the atomic-scale mechanism, ferrimagnetism, is somewhat different). Pieces of magnetite with natural permanent magnetization (lodestones) provided the earliest compasses for navigation. Particles of magnetite were extensively used in magnetic recording media such as core memories, magnetic tapes, floppies, and disks, until they were replaced by cobalt-based materials.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.